CAR T-Cell Therapy Market Report and Forecast 2025-2034
Description
The global CAR T-cell therapy market size was valued at USD 2.50 Billion in 2024, driven by the rising prevalence of cancer across the globe. The market is expected to grow at a CAGR of 15.20% during the forecast period of 2025-2034, with the values likely to rise from USD 2.9 Billion in 2025 to USD 10.29 Billion by 2034.
Global CAR T-Cell Therapy Market Overview
Chimeric antigen receptor (CAR) T-cell therapy is a method of modifying the immune cells, also known as T-cells to fight and destroy cancerous cells in the body. The market demand is majorly driven by growing incidence of cancer. CAR T-cell therapy has also garnered substantial excitement amongst researchers owing to ability to eradicate advanced leukaemia and lymphomas. The market is further propelled by rising investments on CAR T-cell related research and development and subsequent growth in number of FDA approvals for new therapies.
Global CAR T-Cell Therapy Market Trends
Increasing Incidence of Cancer Cases
In 2023, cancer is expected to affect approximately 2 million people in the United States. Non-Hodgkin Lymphoma and Leukaemia are one of the top 12 cancers expected to affect around 80,550 and 59,610 patients respectively. Out of the two, leukaemia is anticipated to cause 23,710 deaths while Non-Hodgkin Lymphoma may lead to 20,180 deaths. Hence, the CAR T-cell therapy market demand is projected to surge in upcoming years, as researchers aim at maximising its application to offer improved patient solutions.
Rising Collaborations Between Key Players
In December 2023, AbelZeta and AstraZeneca entered a partnership to develop the autologous, armoured GPC3-targeting chimeric antigen receptor T Cells (CAR-T) therapy, C-CAR031, designed to treat hepatocellular carcinoma (HCC). C-CAR031 leverages AstraZeneca’s growth factor-beta receptor II (TGFβRII) dominant negative armouring discovery platform along with AbelZeta’s cell therapies. The project pipeline also constitutes tumour-infiltrating lymphocyte therapies. Together, the companies envision at bringing effective and innovative therapeutic alternatives for patients. This also demonstrates the current trend of increasing collaborations which is expected to aid CAR T-cell therapy market growth in upcoming years.
In November 2023, Kite and Arcellx , announced the expansion of their existing partnership, which constituted the development and commercialisation of CART-ddBCMA for relapsed or refractory multiple myeloma. As per the renewal of their agreement, the collaboration will now include lymphomas as well. The candidate is currently under phase 2 clinical development and been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the FDA as well.
Growth in Research Activities to Boost the CAR T-cell Therapy Market Size
With rising technical advancements and deeper understanding of genetics, there has been significant development in CAR-T cell therapies trials. In August 2023, Cellectis provided an update on their ongoing three clinical trials and their evaluation. UCART123, an allogenic CAR-T therapy which targets CD123, occurring in patients with relapsed acute myeloid leukaemia (AML), demonstrated improved anti-tumour activity by sustained lymphodepletion and higher UCART123 cell expansion.
Technical Advancements Fuel a Surge in Approvals
In December 2023, the FDA approved Kite’s Yescarta ® (axicabtagene ciloleucel) CAR T-cell therapy label update. It is the first and only treatment to showcase overall improved survival data for patients with refractory large B-cell lymphoma. The approval is based on the results from ZUMA-7 study which indicated a 27.4% reduction in the death risk when compared to second of care.
In November 2023, Immix Biopharma, Inc. IMMX also revealed that they had received the FDA approval for their new investigational drug which helps the application of NEXICART-2 (NCT06097832) on clinical studies for treatment of relapsed AL amyloidosis. The growth in approvals by the regulatory authorities display a significant CAR T-cell therapy market trend which is projected to help in the market growth in upcoming years.
Global CAR T-Cell Therapy Market Segmentation
The EMR’s report titled “CAR T-Cell Therapy Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
The United States is expected to lead the CAR T-cell therapy market share in the forecast period. This can be attributed to an increased emphasis on providing customised patient care solutions. The rising prevalence of cancer along with existence of key healthcare companies plays a pivotal role in the market growth. The surge in research and development activities is a major element as well.
In the forecast period, Asia Pacific is expected to witness a significant surge in the market value, with countries like India, China and Japan being a centre of attraction. India is expected to grow owing to increasing healthcare infrastructure development and rise in the foreign investments. In October 2023, Immunoadoptive Cell Therapy (ImmunoACT), an IIT Bombay incubated company received the Central Drugs Standard Control Organisation’s (CDSO) marketing authorisation for the first humanised CD19-targeted CAR T-cell therapy product in India. This showcases that the market is expected to emerge significantly in the upcoming years.
Global CAR T-Cell Therapy Market: Competitor Landscape
In July 2023, Pfizer invested USD 25 million equity investment in Caribou Biosciences to develop and extensive allogeneic CAR-T cell therapy for multiple myeloma. The United States based biotech company will invest the money into CB-011, its allogeneic CAR-T cell therapy, which is being studied in a phase 1 clinical trial in patients. It targets the B-cell maturation antigen and is intended to remove the B2M protein and insert a B2M-HLA-E fusion protein to inhibit immune-mediated rejection.
In December 2023, FUJIFILM also announced their USD 200 million investment in cell therapies. This investment is intended to strengthen the company’s manufacturing capacity to support iPSC-derived cell therapies, as well as chimeric antigen receptor (CAR), T-cell receptor (TCR), cytoxic T lymphocyte (CTL), natural killer (NK) and tissue-derived therapies. The rising investments and portfolio expansions demonstrate a generic market trend wherein several companies are stepping in to solidify their presence in the market.
The key features of the CAR T-cell therapy market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Global CAR T-Cell Therapy Market Overview
Chimeric antigen receptor (CAR) T-cell therapy is a method of modifying the immune cells, also known as T-cells to fight and destroy cancerous cells in the body. The market demand is majorly driven by growing incidence of cancer. CAR T-cell therapy has also garnered substantial excitement amongst researchers owing to ability to eradicate advanced leukaemia and lymphomas. The market is further propelled by rising investments on CAR T-cell related research and development and subsequent growth in number of FDA approvals for new therapies.
Global CAR T-Cell Therapy Market Trends
Increasing Incidence of Cancer Cases
In 2023, cancer is expected to affect approximately 2 million people in the United States. Non-Hodgkin Lymphoma and Leukaemia are one of the top 12 cancers expected to affect around 80,550 and 59,610 patients respectively. Out of the two, leukaemia is anticipated to cause 23,710 deaths while Non-Hodgkin Lymphoma may lead to 20,180 deaths. Hence, the CAR T-cell therapy market demand is projected to surge in upcoming years, as researchers aim at maximising its application to offer improved patient solutions.
Rising Collaborations Between Key Players
In December 2023, AbelZeta and AstraZeneca entered a partnership to develop the autologous, armoured GPC3-targeting chimeric antigen receptor T Cells (CAR-T) therapy, C-CAR031, designed to treat hepatocellular carcinoma (HCC). C-CAR031 leverages AstraZeneca’s growth factor-beta receptor II (TGFβRII) dominant negative armouring discovery platform along with AbelZeta’s cell therapies. The project pipeline also constitutes tumour-infiltrating lymphocyte therapies. Together, the companies envision at bringing effective and innovative therapeutic alternatives for patients. This also demonstrates the current trend of increasing collaborations which is expected to aid CAR T-cell therapy market growth in upcoming years.
In November 2023, Kite and Arcellx , announced the expansion of their existing partnership, which constituted the development and commercialisation of CART-ddBCMA for relapsed or refractory multiple myeloma. As per the renewal of their agreement, the collaboration will now include lymphomas as well. The candidate is currently under phase 2 clinical development and been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the FDA as well.
Growth in Research Activities to Boost the CAR T-cell Therapy Market Size
With rising technical advancements and deeper understanding of genetics, there has been significant development in CAR-T cell therapies trials. In August 2023, Cellectis provided an update on their ongoing three clinical trials and their evaluation. UCART123, an allogenic CAR-T therapy which targets CD123, occurring in patients with relapsed acute myeloid leukaemia (AML), demonstrated improved anti-tumour activity by sustained lymphodepletion and higher UCART123 cell expansion.
Technical Advancements Fuel a Surge in Approvals
In December 2023, the FDA approved Kite’s Yescarta ® (axicabtagene ciloleucel) CAR T-cell therapy label update. It is the first and only treatment to showcase overall improved survival data for patients with refractory large B-cell lymphoma. The approval is based on the results from ZUMA-7 study which indicated a 27.4% reduction in the death risk when compared to second of care.
In November 2023, Immix Biopharma, Inc. IMMX also revealed that they had received the FDA approval for their new investigational drug which helps the application of NEXICART-2 (NCT06097832) on clinical studies for treatment of relapsed AL amyloidosis. The growth in approvals by the regulatory authorities display a significant CAR T-cell therapy market trend which is projected to help in the market growth in upcoming years.
Global CAR T-Cell Therapy Market Segmentation
The EMR’s report titled “CAR T-Cell Therapy Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Lisocabtagene Maraleuce
- Idecabtagene Vicleucel
- Ciltacabtegene Autoleucel
- Others
- CD19
- BCMA
- HER2
- GD2
- CD22
- CD30
- CD33
- HER1
- CLDN18
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The United States is expected to lead the CAR T-cell therapy market share in the forecast period. This can be attributed to an increased emphasis on providing customised patient care solutions. The rising prevalence of cancer along with existence of key healthcare companies plays a pivotal role in the market growth. The surge in research and development activities is a major element as well.
In the forecast period, Asia Pacific is expected to witness a significant surge in the market value, with countries like India, China and Japan being a centre of attraction. India is expected to grow owing to increasing healthcare infrastructure development and rise in the foreign investments. In October 2023, Immunoadoptive Cell Therapy (ImmunoACT), an IIT Bombay incubated company received the Central Drugs Standard Control Organisation’s (CDSO) marketing authorisation for the first humanised CD19-targeted CAR T-cell therapy product in India. This showcases that the market is expected to emerge significantly in the upcoming years.
Global CAR T-Cell Therapy Market: Competitor Landscape
In July 2023, Pfizer invested USD 25 million equity investment in Caribou Biosciences to develop and extensive allogeneic CAR-T cell therapy for multiple myeloma. The United States based biotech company will invest the money into CB-011, its allogeneic CAR-T cell therapy, which is being studied in a phase 1 clinical trial in patients. It targets the B-cell maturation antigen and is intended to remove the B2M protein and insert a B2M-HLA-E fusion protein to inhibit immune-mediated rejection.
In December 2023, FUJIFILM also announced their USD 200 million investment in cell therapies. This investment is intended to strengthen the company’s manufacturing capacity to support iPSC-derived cell therapies, as well as chimeric antigen receptor (CAR), T-cell receptor (TCR), cytoxic T lymphocyte (CTL), natural killer (NK) and tissue-derived therapies. The rising investments and portfolio expansions demonstrate a generic market trend wherein several companies are stepping in to solidify their presence in the market.
The key features of the CAR T-cell therapy market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Autolus Therapeutics
- CARsgen Therapeutics Co.Ltd.
- Juno Therapeutics, Inc.
- Sorrento Therapeutics, Inc.
- Bluebird bio, Inc.
- CELGENE CORPORATION
- Eureka Therapeutics Inc.
- Avacta Life Sciences Ltd.
- Calyxt Inc.
- Celyad Oncology SA
- Fortress Biotech, Inc
- IMMUNE THERAPEUTICS, INC
- Alaunos Therapeutics, Inc.
- Novartis AG
- Gilead Sciences, Inc.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global CAR T-Cell Therapy Market Overview
- 3.1 Global CAR T-Cell Therapy Market Historical Value (2018-2024)
- 3.2 Global CAR T-Cell Therapy Market Forecast Value (2025-2034)
- 4 Global CAR T-Cell Therapy Market Landscape
- 4.1 Global CAR T-Cell Therapy Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global CAR T-Cell Therapy Product Landscape
- 4.2.1 Analysis by Drug Type
- 4.2.2 Analysis by Antigen Type
- 4.2.3 Analysis by Application
- 5 Global CAR T-Cell Therapy Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global CAR T-Cell Therapy Market Segmentation
- 6.1 Global CAR T-Cell Therapy Market by Drug Type
- 6.1.1 Market Overview
- 6.1.2 Axicabtagene Ciloleucel
- 6.1.3 Tisagenlecleucel
- 6.1.4 Brexucabtagene Autoleucel
- 6.1.5 Lisocabtagene Maraleuce
- 6.1.6 Idecabtagene Vicleucel
- 6.1.7 Ciltacabtegene Autoleucel
- 6.1.8 Others
- 6.2 Global CAR T-Cell Therapy Market by Antigen
- 6.2.1 Market Overview
- 6.2.2 CD19
- 6.2.3 BCMA
- 6.2.4 HER2
- 6.2.5 GD2
- 6.2.6 CD22
- 6.2.7 CD30
- 6.2.8 CD33
- 6.2.9 HER1
- 6.2.10 CLDN18
- 6.3 Global CAR T-Cell Therapy Market by Application
- 6.3.1 Market Overview
- 6.3.2 Acute Lymphocytic Leukemia
- 6.3.3 Chronic Lymphocytic Leukemia
- 6.3.4 Diffuse Large B-Cell Lymphoma (DLBCL)
- 6.3.5 Follicular Lymphoma
- 6.3.6 Mantle Cell Lymphoma
- 6.3.7 Multiple Myeloma
- 6.3.8 Glioblastoma
- 6.3.9 Sarcoma
- 6.3.10 Neuroblastoma
- 6.3.11 Acute Myeloid Leukemia
- 6.3.12 Breast Cancer
- 6.3.13 Pancreatic Cancer
- 6.3.14 Hepatocellular Carcinoma
- 6.3.15 Colorectal Cancer
- 6.3.16 Others
- 6.4 Global CAR T-Cell Therapy Market by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America CAR T-Cell Therapy Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe CAR T-Cell Therapy Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific CAR T-Cell Therapy Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Others
- 10 Latin America CAR T-Cell Therapy Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa CAR T-Cell Therapy Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by Year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding & Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 INDIA CDSCO
- 16.1.4 JAPAN PMDA
- 16.1.5 Others
- 17 Supplier Landscape
- 17.1 Autolus Therapeutics
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 CARsgen Therapeutics Co.Ltd.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Juno Therapeutics, Inc.
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Sorrento Therapeutics, Inc.
- 17.4.1 Financial Analysis
- 17.4.2 Financial Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Bluebird bio, Inc.
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 CELGENE CORPORATION
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Eureka Therapeutics Inc.
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Avacta Life Sciences Ltd.
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Calyxt Inc.
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Celyad Oncology SA
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Fortress Biotech, Inc
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 IMMUNE THERAPEUTICS, INC
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Alaunos Therapeutics, Inc.
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Novartis AG
- 17.14.1 Financial Analysis
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications
- 17.15 Gilead Sciences, Inc.
- 17.15.1 Financial Analysis
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisitions
- 17.15.5 Certifications
- 18 Global CAR T-Cell Therapy Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
